Would Outcomes-Based Contracting be Beneficial for Orphan Drugs?


Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.

Outcomes-based contracting can be very beneficial for specialty pharmacies, and we certainly have a role to play. We are at the center of the patients care once they leave the physician’s office, particularly with the new oral and self-administered medications.

That being said, there’s only certain factors that as a pharmacy we can control related to those outcomes. So, I think where the value comes into outcomes-based contracting is really helping us as pharmacies show what we can control and how we can impact patient outcomes.

Related Videos
Emergency CPR on a Man who has Heart Attack , One Part of the Process Resuscitation (First Aid) - Image credit: Platoo Studio | stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.